

2024 Current Fiscal Year Report: Center for Substance Abuse Prevention Drug Testing Advisory Board

Report Run Date: 04/17/2024 12:16:04 AM

1. Department or Agency

Department of Health and Human Services

2. Fiscal Year

2024

3. Committee or Subcommittee

Center for Substance Abuse Prevention Drug
Testing Advisory Board

3b. GSA

Committee

No.

852

4. Is this New During Fiscal Year?

No

5. Current Charter

06/25/2022 06/25/2024

6. Expected Renewal Date

7. Expected Term Date

8a. Was Terminated During Fiscal Year?

No

8b. Specific Termination Authority

8c. Actual Term Date

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority

Authorized by Law

12. Specific Establishment Authority

42 U.S.C. § 217a, Section
222 of the Public Health
Service Act

13. Effective Date

10/27/1986

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Scientific Technical Program
Advisory Board

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a. Open

0

17b. Closed

0

17c. Partially Closed

0

Other Activities

0

17d. Total

0

Meetings and Dates

No Meetings

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$0.00	\$0.00
18d. Total	\$0.00	\$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

The CSAP Drug Testing Advisory Board's recommendations are an essential prerequisite for implementation of new science into regulation and practice. The CSAP Drug Testing Advisory Board provides advice to the Assistant Secretary for Mental Health and Substance Use, SAMHSA, as the Agency responsible for establishing federal agency workplace drug testing policies in accordance with Executive Order 12564, based on an ongoing review of the direction, scope, balance, and emphasis of the Agency's drug

testing activities and the drug testing laboratory certification program. The CSAP Drug Testing Advisory Board reviews SAMHSA's program for national laboratory certification for federal workplace drug testing programs as required by Public Law 100-71 and as described in the Mandatory Guidelines for Federal Workplace Drug Testing Programs. It recommends areas for emphasis or de-emphasis, new or changed directions, and mechanisms or approaches for implementing recommendations. The CSAP Drug Testing Advisory Board also reviews the science associated with alternate specimen matrices and new drugs of abuse and the methods necessary to detect their presence.

20b. How does the Committee balance its membership?

The CSAP Drug Testing Advisory Board consists of three nonvoting ex officio members who are officers or employees of the United States Government, as the Assistant Secretary for Mental Health and Substance Use, SAMHSA, determines necessary for the CSAP Drug Testing Advisory Board to effectively carry out its functions. The 10 public members are appointed by the Assistant Secretary, SAMHSA. Of the 10 appointed members, 8 are recognized as experts in either analytical forensic toxicology, in specimen collection procedures for regulated drug testing programs, and interpreting drug testing results. The appointed individuals should represent a variety of disciplines related to forensic drug testing, such as experience in a forensic drug testing laboratory, related academic research, toxicological research, the Medical Review Officer community, or technical expertise from other government agencies involved with drug testing issues, including military drug testing programs. Of

the additional two appointed members, one shall represent users of SAMHSA's certified drug testing laboratories and drug-free workplace programs and processes and one shall represent individuals tested in federal or federally-regulated workplace drug testing programs. All Board members who are not officers or employees (full-time or permanent part-time) of the United States Government shall serve as Special Government Employees. Appointments are made by paying close attention to experience and expertise as well as equitable gender representation, race/ethnicity representation, and geographic distribution. Board members advise SAMHSA executive leadership on policy and scientific and technical program development.

20c. How frequent and relevant are the Committee Meetings?

CSAP Drug Testing Advisory Board convened two times during FY 2023. Four meetings are tentatively scheduled for fiscal year 2024. The CSAP Drug Testing Advisory Board was charged during this fiscal year with evaluating the scientific supportability of the hair matrix as an alternative specimen for the inclusion in the Federal Workplace Drug Testing Programs. That work has proved challenging and time intensive. The CSAP Drug Testing Advisory Board also received federal drug testing updates from the Department of Transportation, the Department of Defense, the Nuclear Regulatory Commission, and the Federal Drug-Free Workplace Programs. In addition, the CSAP Drug Testing Advisory Board will continue to assist the Agency in recommending revisions to the Mandatory Guidelines for testing alternative specimens in addition to current matrixes and additional Schedule II drugs, addressing the impact of new drugs of abuse in the workplace,

and assessing the methods that are available to detect their use. The CSAP Drug Testing Advisory Board will review the Agency's National Laboratory Certification Program that was established as required by the Supplemental Appropriations Act of 1987 (Public Law 100-71) and as described in the Mandatory Guidelines. These meetings were relevant to carry out the board's functions.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The CSAP Drug Testing Advisory Board is composed of both scientific and professional members who provide advice to the Assistant Secretary for Mental Health and Substance Use on improving the quality of services for forensic workplace drug testing, assessing the science and technology used in drug analyses, improving the quality of related laboratory services and systems for drug testing, generating standards for laboratory certification for federal workplace drug testing programs, and guiding national policy in these areas. There is no existing committee or other alternative mechanism that can provide the same expert advice as that provided by the CSAP Drug Testing Advisory Board.

20e. Why is it necessary to close and/or partially closed committee meetings?

The closed portions of the Board's meetings involve discussions by the Board of proposed revisions to the Mandatory Guidelines for Federal Workplace Drug Testing Programs, unpublished and confidential research material, and the review of sensitive National Laboratory Certification Program information. These portions of the meetings are closed to the public as determined by the Assistant Secretary for Mental Health and

Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(9)(B) and 5 U.S.C. App. 2, Section 10(d).

21. Remarks

None. GSA Comment: The agency did not complete the FY23 ACR for this committee.

Designated Federal Officer

Lisa Davis Senior Toxicology Policy Advisor

Committee Members	Start	End	Occupation	Member Designation
Baczara, Bohdan	11/01/2021	06/17/2024	Deputy Director DOT	Ex Officio Member
Engelhart, David	05/03/2021	05/02/2025	Omega Laboratories/Lab Director	Special Government Employee (SGE) Member
Everson, E.	05/01/2022	04/30/2026	Attorney. Interprets Drug Testing Results	Special Government Employee (SGE) Member
Flegel, Ronald	11/01/2014	06/17/2024	Director, Division of Workplace Programs, Center for Substance Abuse Prevention, SAMHSA	Ex Officio Member
Hahn, Dawn	05/01/2023	04/30/2027	Toxicology Expert - Laboratory	Special Government Employee (SGE) Member
Kotarek, Joseph	11/01/2021	06/17/2024	Branch Chief FDA	Ex Officio Member
Roberts, David	11/01/2021	10/31/2025	Laboratory Director	Special Government Employee (SGE) Member
Ruggery, Bryan	05/01/2023	04/30/2027	Toxicology Expert - DEA	Ex Officio Member
Stockdale, Alison	05/26/2020	06/17/2024	DOI	Ex Officio Member
Stuyt, Elizabeth	11/01/2021	10/31/2025	Addiction Psychologist	Special Government Employee (SGE) Member
Zaleski, Brian	10/01/2022	10/31/2026	Nuclear Regulatory Commission	Ex Officio Member

Number of Committee Members Listed: 11

Narrative Description

The Board provides advisory recommendations regarding improvements in the scientific aspects of forensic workplace drug testing, thereby, impacting on the Agency's efforts to prevent substance abuse among federal employees.

What are the most significant program outcomes associated with this committee?

Checked if
Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input checked="" type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input checked="" type="checkbox"/>
Increased customer satisfaction	<input checked="" type="checkbox"/>
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

Outcome Comments

NA

What are the cost savings associated with this committee?

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

It is extremely difficult to determine the cost savings associated with identifying a federal employee as positive for an illicit substance.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

38

Number of Recommendations Comments

From FY 1994 to FY 2023, the CSAP DTAB produced 38 recommendations. The Oral Fluid Mandatory Guidelines was finalized and released in the Federal Register on October 25, 2019 with effective date of January 1, 2020. Current work is being conducted on the proposed Hair Mandatory Guidelines.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

97%

% of Recommendations Fully Implemented Comments

Since the beginning of the Board, approximately 97% of the Board's recommendations have been fully implemented without any changes. These recommendations concerned revisions to the Mandatory Guidelines, urine and oral fluid collection handbooks, medical review officer manuals, and other National Laboratory Certification Program documents and policies.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

3%

% of Recommendations Partially Implemented Comments

The Board's recommendations regarding changes in the scientific and administrative aspects of the Federal Workplace Drug Testing Programs are occasionally modified by the Department based on comments received from other Health and Human Services agencies; other federal departments, including the Department of Transportation, the Department of Defense, and the Nuclear Regulatory Commission; and the Office of Management and Budget. The hair recommendation is in the proposed process.

Does the agency provide the committee with feedback regarding actions taken to

implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

Feedback is provided to the Board members on the actions taken by the Agency on the Board's recommendations at each Board meeting, by e-mailing documents to the Board members. Additionally, when policies are implemented, Board members are provided copies. The public can obtain information on agency feedback about recommendations recorded in the meeting minutes that are open to the public.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input checked="" type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

NA

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

Access Comments

N/A